Breaking: FDA Greenlights Profound Medical's TULSA AI Module
- September 26th, 2023
- 644 views
Shares of Profound Medical Corp. (Nasdaq: PROF) surged by more than 10% in after-hours trading after it announced FDA clearance for its Thermal Boost module in conjunction with TULSA-PRO, which allows surgeons to treat various prostate conditions, including cancer and benign prostatic hyperplasia (BPH).
The Thermal Boost module, Profound's first FDA-cleared TULSA AI module, enables surgeons to temporarily increase the ablation target temperature in areas where advanced-stage cancer might be present, improving confidence in effective cancer cell ablation.
$PROF was trading at $10.94 in the extended session, up $1.04 (+10.51%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026




Member Login